The European Commission approves Astellas Pharma’s (OTCPK:ALPMY)
XOSPATA (gilteritinib) for the treatment of adult patients with
relapsed/refractory FLT3 mutation-positive acute myeloid leukemia (AML),
a type of AML with a poor prognosis.
The company owns global rights to the kinase inhibitor under an agreement with licensor Kotobuki Pharmaceutical Co., Ltd.
The product was approved in the U.S. and Japan in 2018.
https://seekingalpha.com/news/3509607-astellas-gilteritinib-okd-europe-type-aml
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.